Edition:
United Kingdom

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

20.04USD
20 Apr 2018
Change (% chg)

$-0.46 (-2.24%)
Prev Close
$20.50
Open
$20.46
Day's High
$20.91
Day's Low
$19.81
Volume
30,374
Avg. Vol
39,696
52-wk High
$28.95
52-wk Low
$13.37

Chart for

About

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are... (more)

Overall

Beta: --
Market Cap(Mil.): $481.46
Shares Outstanding(Mil.): 20.53
Dividend: --
Yield (%): --

Financials

  SNNA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.39 -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Sienna Biopharmaceuticals Appoints John Smither As CFO

* SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER

21 Mar 2018

BRIEF-Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56

* SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

15 Mar 2018

BRIEF-Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS

12 Mar 2018

BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125

14 Feb 2018

BRIEF-Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​

* Sienna Biopharmaceuticals reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

* Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

24 Oct 2017

Earnings vs. Estimates